By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interview with Dr. Richard Straube Regarding Upcoming Phase 3 Data for SGX301 in CTCL Soligenix, Inc. (NASDAQ:SNGX) recently announced the completion of enrollment in the Phase 3 clinical trial of SGX301 in patients with cutaneous T cell lymphoma (CTCL).… Read More..
Anticipates $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018; Fourth Quarter Year-Over-Year Revenue Growth Approximately 99% SOUTH ORANGE, NJ, January 6, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced preliminary… Read More..
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on December 26, 2019, the United States District Court, Southern District of New York (the “Court”) ruled on several motions related to… Read More..